<DOC>
	<DOCNO>NCT01321372</DOCNO>
	<brief_summary>Hematology patient high risk invasive fungal infection ( IFI ) treat voriconazole ( VOR ) Princess Margaret Hospital ( PMH ) . It critical patient ' serum drug level within therapeutic range undergo treatment . The primary objective study determine whether clinical response ( complete/partial/failure ) directly correlate patient ' blood VOR drug level . In patient whose disease progression associate inadequate voriconazole ( VOR ) drug level , serum drug level determination allow dose adjustment , thereby prevent disease progression . Patients extensive metabolizers may subtherapeutic VOR level lead treatment failure whereas , poor metabolizers may high drug level cause toxicity . Isoenzyme CYP2C19 exhibit genetic polymorphism . Genotyping test also helpful determine patient risk subject extreme spectrum drug level .</brief_summary>
	<brief_title>An Observational Analysis Voriconazole Therapeutic Drug Concentration Monitoring , Pharmacogenomics Clinical Outcome Correlations High-risk Hematology Patients</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Acute leukemia ( include myelogenous lymphocytic ) patient remission induction chemotherapy , reinduction chemotherapy consolidation chemotherapy whose antifungal treatment include voriconazole . Patients subscribe voriconazole probable proven fungal infection microbiological/cytohistological evidence fine needle aspirate bronchoalveolarlavage mean . Patients also image positive lose dose CT result depict halo sign crescent sign suggestive invasive fungal infection . Patients must able tolerate oral intake medication . Patients unable tolerate oral administration combination severe mucositis ( &gt; = grade 3 ) , nausea/vomiting ( &gt; = grade 3 ) , diarrhea ( &gt; =grade 2 ) , neutropenic enterocolitis ( &gt; = grade3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>